VIDEO: Physicians must be aware of hepatobiliary manifestations in IBD
ORLANDO — In this exclusive video perspective from Advances in IBD 2018, Edward V. Loftus Jr., MD, professor of medicine in the division of gastroenterology and hepatology at the Mayo Clinic, Rochester, Minn., and chief medical editor of Healio Gastroenterology and Liver Disease, discusses his presentation on hepatobiliary manifestations of inflammatory bowel disease.
“This would include generic things like fatty liver, cholelithiasis,” he said. “We know that these occur more commonly in IBD patients, and specifically with cholelithiasis, in Crohn’s disease patients.”
Loftus said hepatobiliary manifestations also included things that were specific to IBD, including primary sclerosing cholangitis, which affects approximately 5% of patients with IBD.
He also discussed complications of IBD therapy, including liver enzyme abnormalities related to thiopurines, as well as complications related to anti-TNF therapy.
“There’s a small percentage of patients who get transaminase elevations starting on an anti-TNF,” he said. “It’s often drug-specific. I know in my own practice I’ve had several cases where I discontinued an anti-TNF and then started a second anti-TNF. It did not see the liver enzyme elevations.”
Disclosure: Loftus reports financial ties to AbbVie, Allergan, Amgen, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Genentech, Gilead, Janssen, Medimmune, Pfizer, Robarts Clinical Trials and Takeda.